BioPharma Drive: Drug Pricing

SEPTEMBER 8, 2024

Study results provide much-anticipated details to Summit’s claim earlier this year that its drug “decisively beat” Merck’s dominant immunotherapy.

Drugs 135

Drugs 135

Drugs.com

SEPTEMBER 8, 2024

SUNDAY, Sept. 8, 2024 -- Getting older tends to go hand in hand with failing vision, but eye experts say there are things you can do to preserve your sight as you age.The risk of age-related macular degeneration (AMD) and diabetic retinopathy.

111

111

New Drug Approvals

SEPTEMBER 8, 2024

Palopegteriparatide Yorvipath , FDA 2024, 8/9/2024, To treat hypoparathyroidism G2N64C3385 2222514-07-8 Palopegteriparatide UNII-G2N64C3385 ACP-014 Mpeg 40000-teriparatide Palopegteriparatide [INN] Transcon parathyroid hormone (1-34) Transcon pth (1-34) Palopegteriparatide [USAN] TransCon PTH WHO 11060 Palopegteriparatide Palopegteriparatide is a human parathyroid hormone analogue corresponding to amino acid residues 1 – 34 of human parathyroid hormone, to which a methoxy polyethylene glycol (mo

FDA 62

FDA International FDA Approval Trials 62

Perficient: Drug Development

SEPTEMBER 8, 2024

UX in Universal Design Series: Key Principles of Usability for Physical Disabilities in Health Systems In healthcare, accessibility and usability are essential to ensuring that all patients, including those with physical disabilities, receive equal care. For individuals with physical disabilities, navigating healthcare facilities and interacting with medical devices can pose significant challenges.

Treatment 52

Treatment 52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

New Drug Approvals

SEPTEMBER 8, 2024

Aneratrigine 2097163-74-9 5-chloro-2-fluoro-4-[4-fluoro-2-[methyl-[2-(methylamino)ethyl]amino]anilino]- N -(1,3-thiazol-4-yl)benzenesulfonamide 5-chloro-2-fluoro-4-((4-fluoro-2-(3-(methylamino)pyridin-1-yl)phenyl)amino)-N-(thiazol-4-yl)benzenesulfonamide hydrochloride Benzenesulfonamide, 5-chloro-2-fluoro-4-[[4-fluoro-2-[methyl[2-(methylamino)ethyl]amino]phenyl]amino]-N-4-thiazolyl- C 19 H 20 ClF 2 N 5 O 2 S 2 488.0 g/mol UNII 6A5ZY5LT78 WHO SYN Assignee: Daewoong Pharmaceutical Co., Ltd.

International 62

International Production Pharmaceuticals 62

Perficient: Drug Development

SEPTEMBER 8, 2024

Designing health systems that are inclusive for individuals with physical disabilities is crucial for ensuring equal access to healthcare. Despite progress, many healthcare environments still present significant challenges for these patients. In this installment of the UX in Universal Design Series, we will explore the challenges faced when designing for physical disabilities and highlight the opportunities that exist to make health systems more accessible, functional, and inclusive.

Regulations 52

Regulations Compliance Treatment 52

New Drug Approvals

SEPTEMBER 8, 2024

Seladelpar cas 851528-79-5 C 21 H 23 F 3 O 5 S, 444.47 fda approved 8/14/2024, To treat primary biliary cholangitis (PBC), Livdelzi Ingredient UNII CAS InChI Key Seladelpar lysine N1429130KR 928821-40-3 WTKSWPYGZDCUNQ-JZXFCXSPSA-N (+)-MBX-8025 MBX 8025 MBX-8025 MBX8025 RWJ-800025 ((4-(((2R)-2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)THIO)-2-METHYLPHENYL)OXY)ACETIC ACID (4-(((2R)-2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)SULFANYL)-2-METHYLPHENOXY)ACETIC ACID PEROXISOME PROLIFERATOR ACTIVAT

FDA 62

FDA Licensing Licensing FDA Approval 62